We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

HAL:NYSEHalliburton Company Analysis

Data as of 2026-03-10 - not real-time

$35.29

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Halliburton is trading at $35.29, comfortably above its 20‑day SMA of $34.90 and the 50‑day SMA of $33.36, confirming a bullish price momentum despite a bearish MACD histogram. RSI at 56.7 indicates the stock is not yet overbought, while volume is on an increasing trend, supporting the upward move. Recent earnings beat and the declaration of a $0.17 per‑share dividend have bolstered investor sentiment, reflected in an "Extreme Greed" market tone (fear‑greed index 80.66). However, the DCF fair‑value estimate of $29.14 sits well below the current price, implying the market is pricing in optimistic growth assumptions. The 30‑day volatility of ~28% and a computed beta of ~1.25 suggest heightened price swings relative to the broader market, underscoring the need for disciplined positioning.
Strategically, the new Indonesia MoU and AI‑driven service offerings provide a growth catalyst, while a payout ratio of ~45% and solid free cash flow support dividend sustainability. Investors should weigh the upside potential against the valuation premium and sector cyclicality before committing.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price above short‑term moving averages
  • Increasing volume and bullish trend direction
  • Bearish MACD histogram and overvalued price relative to DCF

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Forward EPS growth and lower forward PE (13.1)
  • Strategic Indonesia partnership and AI service expansion
  • Sustainable dividend yield of ~2% with 45% payout ratio

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Cyclical nature of energy‑services sector
  • Current valuation premium over fair value
  • Stable cash generation offset by high debt-to-equity

Key Metrics & Analysis

Financial Health

Revenue Growth0.80%
Profit Margin5.78%
P/E Ratio23.5
ROE12.27%
ROA7.37%
Debt/Equity79.16
P/B Ratio2.8
Op. Cash Flow$2.9B
Free Cash Flow$2.1B
Industry P/E20.5

Technical Analysis

TrendBullish
RSI56.7
Support$33.10
Resistance$37.03
MA 20$34.90
MA 50$33.36
MA 200$26.02
MACDBearish
VolumeIncreasing
Fear & Greed Index80.66

Valuation

Fair Value$29.14
Target Price$36.50
Upside/Downside3.44%
GradeOvervalued
TypeBlend
Dividend Yield1.96%

Risk Assessment

Beta1.25
Volatility28.56%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.